Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of a controlled release
formulation of pregabalin administered once daily as compared to placebo in the treatment of
fibromyalgia. All patients will receive pregabalin; half of the patients will receive placebo
at some point in the study.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.